Collaborations

Multi-site Trials Investigators

 

Principal Investigators for multi-site trials for which the Berman Center has served either as a regional coordinator or as a clinical site:
Colin B, Baignet, BM

University of Oxford, Oxford, United Kingdom
SHARP, Study of Heart and Renal Protection

Oscar Benavente, MD

University of Texas Health Science Center, San Antonio, TX
SPS3, Secondary Prevention of Small Subcortical Strokes

Merit Cudkowicz, MD

Massachusetts General Hospital/Harvard Medical School, Boston, MA
Celebrex in ALS

Hertzel Gerstein, MD

Professor of Medicine and Chief of Division of Endocrinology
McMaster University Faculty of Health Sciences
Hamilton, Ontario, Canada
ORIGIN, Outcome Reduction with Initial Glargine Intervention (Co-principal Investigator)
DREAM, Diabetes Reduction Assessment with Ramipril and Rosiglitazone
Medication (Co-principal Investigator)

Charles H. Hennekens, MD, DrPh

Mount Sinai Medical Center
TACT, Trial to Assess Chelation Therapy (Co-principal Investigator)

Gervasio A. Lamas, MD

Mount Sinai Medical Center
TACT, Trial to Assess Chelation Therapy (Co-principal Investigator)

Martin Landray, BM

University of Oxford, Oxford, United Kingdom
SHARP, Study of Heart and Renal Protection

Jeffery Probstfield, MD

University of Washington School of Medicine
ORIGIN, Outcome Reduction with Initial Glargine Intervention (Principal Investigator for U.S. Regional Coordinating Center)

Eric Sorenson, MD

Mayo Clinic, Rochester, MN
IGF-I (Myotrophin) in ALS

Salim Yusuf, MD

Professor of Medicine and Chief of Division of Cardiology
McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada
ORIGIN, Outcome Reduction with Initial Glargine Intervention (Co-principal Investigator)
DREAM, Diabetes Reduction Assessment with Ramipril and Rosiglitazone
Medication (Co-principal Investigator)
ONTARGET/TRANSCEND
OnTarget: Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial: A large, Simple Randomized Trial of an Angiotensin II Receptor Antagonist (Telmisartan) and an ACE-Inhibitor (Ramipril) in Patients at High Risk for Cardiovascular Events
Transcend: Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease

Robert Byington, PhD

Wake Forest School of Medicine, Winston-Salem, NC                                                                         ACCORD, Action to Control Cardiovascular Risks in Diabetes

John McNeil, PhD, MSc

Monash University, Melbourne, Australia ASPREE, ASPirin in Reducing Events in the Elderly